Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREFER-AF: NOACs Vascular Protective Effects
NCT02544932Phase 3Unknown
- Sponsor
- Kyung Hee University Medical Center
- Start
- Oct 2015
- Primary completion
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of dabigatran, rivaroxaban in Atrial fibrillation (AFib), sponsored by Kyung Hee University Medical Center. Status: unknown.
02
Drugs
dabigatranrivaroxaban
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT02544932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02544932.